002332SZSE

Independent Director's Performance Report 2025

✨ AI Summary

This report details the performance of Independent Director Hao Yunhong for Zhejiang Xianju Pharmaceutical Co., Ltd. in 2025. It covers personal background, adherence to independence requirements, attendance at board and shareholder meetings, participation in special committees, and communication with stakeholders. The director fulfilled duties diligently, ensuring compliance and protecting shareholder interests.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Zhejiang Xianju Pharmaceutical Co., Ltd. Independent Director's Performance Report 2025

I, Hao Yunhong, as an independent director of Zhejiang Xianju Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") for the Eighth and Ninth Boards of Directors, have strictly adhered to the provisions and requirements of relevant laws and regulations in 2025, diligently and faithfully performed my duties as an independent director, and protected the overall interests of the Company and the legitimate rights and interests of all shareholders, especially small and medium shareholders. The performance report for 2025 is as follows:

I. Basic Information of Independent Director

  1. Personal Work Experience, Professional Background, and Concurrent Positions I, Hao Yunhong, was born in November 1962, am a Chinese national with no permanent overseas residency, hold a Ph.D. in Economics from Northwest University, and completed post-doctoral research in Business Administration at Xi'an Jiaotong University. I previously served as an Assistant Professor, Lecturer, and Associate Professor at Yan'an University, and as a Professor at Shanxi University of Finance and Economics. I am currently a Professor and doctoral supervisor in the School of Business Administration at Zhejiang Gongshang University. I have served as an independent director of the Company since May 2021.

  2. Circumstances Affecting Independence In 2025, I did not have any circumstances affecting my independence as required by the "Administrative Measures for Independent Directors of Listed Companies," the Shenzhen Stock Exchange's "Guidelines for the Standardized Operation of Listed Companies on the Main Board No. 1," and the "Company's Independent Director System."

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.